Alnylam Pharmaceuticals Reports First Quarter 2016 Financial Results and Highlights Recent Period Progress
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/27/2026
- S&P 500 ends lower; chips tumble and Moderna rallies
- SpaceX weighs Starlink mobile service to US consumers, FT reports
- U.S. chip stocks retreat after Apple price hikes stoke fears over AI trade
- Morgan Stanley flags Fed hike risk if unemployment drops below 4%
- UBS trims AI portfolio exposure to semis and hardware after recent rally
Jefferies Cuts Price Target on Alnylam Pharma (ALNY) Following 1Q
May 3, 2016 9:40 AM EDTJefferies maintained a Buy rating on Alnylam Pharmaceuticals (NASDAQ: ALNY), and cut the price target to $119.00 (from $122.00), following the company's 1Q earnings report. ALNY reported 1Q16 revenues of $7.3M, ahead of consensus estimates of 7.8M. The company ended the quarter with... More
Leerink Cuts Alnylam (ALNY) PT to $107
May 3, 2016 8:14 AM EDTLeerink Partners analyst, Michael Schmidt, recapped the Alnylam Pharmaceuticals (NASDAQ: ALNY) pipeline update from 1Q results and cut his price target but maintained his Outperform rating. The PT drops to $107 from $120 but still offers 55% upside.
Pipeline updates: (1) Enrollment of the Revusiran Ph III trial in... More
Alnylam Pharma (ALNY) Misses Q1 EPS by 16c
May 2, 2016 4:03 PM EDTAlnylam Pharma (NASDAQ: ALNY) reported Q1 EPS of ($1.21), $0.16 worse than the analyst estimate of ($1.05). Revenue for the quarter came in at $7.3 million versus the consensus estimate of $7.75 million.
At March 31, 2016, Alnylam had cash, cash equivalents and total marketable securities of $1.21 billion, as compared to $1.28... More
